INTELLIA THERAPEUTICS INC. - COMMON STOCK

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates

27 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

24 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

08 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

05 May 2022 07:30:01 By Nasdaq GlobeNewswire

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

02 May 2022 16:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference

02 May 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates

28 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia 

09 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia

01 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

28 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress

24 Feb 2022 07:30:01 By Nasdaq GlobeNewswire

Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies

23 Feb 2022 08:00:02 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022

17 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics

03 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022

06 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

05 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

05 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer

20 Dec 2021 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

13 Dec 2021 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

22 Nov 2021 07:30:00 By Nasdaq GlobeNewswire